Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer

Oncogene. 2010 Jun 10;29(23):3374-85. doi: 10.1038/onc.2010.86. Epub 2010 Mar 22.

Abstract

Elevated expression of the integrin-linked kinase (ILK) has been observed in a variety of cancers and has been further correlated with poor clinical outcome. Here, we show that mammary epithelial disruption of ILK results in a profound block in mammary tumor induction. Consistent with these observations, inhibition of ILK function in ErbB2-expressing cells with small molecule inhibitor or RNA interference resulted in profound block in their in vitro invasive properties due to the induction of apoptotic cell death. The rare ILK-deficient tumors that eventually arose overcame this block in tumor induction by an upregulation of ErB3 phosphorylation. These observations provide direct evidence that ILK has a critical role in the initiation phase of ErbB2 tumor induction.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Breast Neoplasms / etiology*
  • Disease Progression
  • Female
  • Humans
  • Mammary Neoplasms, Experimental / etiology*
  • Mammary Tumor Virus, Mouse / genetics
  • Mice
  • Mice, Transgenic
  • Neoplasm Invasiveness
  • Neoplasm Metastasis
  • Protein Serine-Threonine Kinases / physiology*
  • Receptor, ErbB-2 / physiology*
  • Signal Transduction

Substances

  • integrin-linked kinase
  • Receptor, ErbB-2
  • Protein Serine-Threonine Kinases